search
Back to results

Dental Device for Treatment of Sleep Apnea (OSA-MAD)

Primary Purpose

Sleep Apnea Syndromes

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Mandibular advancement device
Sponsored by
Ulysses Magalang MD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Sleep Apnea Syndromes focused on measuring Sleep Apnea Syndromes, Insulin Resistance, Mandibular advancement device

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Apnea-hypopnea index (AHI) of at least 20 events/hr based on overnight polysomnography
  • > 18 years of age
  • Unable to tolerate or refuse CPAP treatment

Exclusion Criteria:

  • Known diabetes mellitus
  • Body mass index (BMI) > 45 kg/m2
  • Uncontrolled hypertension
  • Known congestive heart failure
  • Use of illicit drugs
  • Excessive alcohol consumption, defined as:

    • More than 3 glasses of wine a day
    • More than 3 beers a day
    • More than 60 mL of hard liquor a day
  • Room air oxyhemoglobin saturation < 90%
  • Use of home oxygen
  • Use of corticosteroids
  • Unable to give voluntary consent

Sites / Locations

  • The Ohio State University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Mandibular advancement device

No mandibular advancement device

Arm Description

Subject is evaluated when receiving intervention with mandibular advancement device.

Subject is evaluated when not receiving treatment with mandibular advancement device.

Outcomes

Primary Outcome Measures

Treatment of OSA with mandibular advancement device results in improvements in insulin sensitivity

Secondary Outcome Measures

Treatment of OSA with mandibular advancement device increases the levels of high-molecular-weight adiponectin in the circulation
Treatment of OSA with mandibular advancement device improves psychological adjustment.

Full Information

First Posted
October 30, 2009
Last Updated
July 19, 2021
Sponsor
Ulysses Magalang MD
search

1. Study Identification

Unique Protocol Identification Number
NCT01005940
Brief Title
Dental Device for Treatment of Sleep Apnea
Acronym
OSA-MAD
Official Title
Health Outcomes of Treatment of Obstructive Sleep Apnea With Dental Devices
Study Type
Interventional

2. Study Status

Record Verification Date
July 2021
Overall Recruitment Status
Completed
Study Start Date
January 2010 (Actual)
Primary Completion Date
June 2014 (Actual)
Study Completion Date
December 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Ulysses Magalang MD

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is being done to see if treatment of obstructive sleep apnea (OSA) with a mandibular advancement device (MAD) shows an increase in the quality of life. Many patients prefer to call them mandibular advancers, jaw advancers, jaw advancement splints, jaw advancement devices, anti-snoring mouthpieces, or oral appliances for the treatment of snoring and mild to moderate obstructive sleep apnea. The investigators will also see how helpful the mandibular advancement device is on insulin resistance.
Detailed Description
Patients with obstructive sleep apnea (OSA) will be included in this prospective controlled trial. OSA patients who are unable to tolerate CPAP or refuse CPAP(Continuous positive airway pressure) (and who are deemed appropriate by their attending physician for dental device treatment of OSA will be randomized to a control group (no MAD treatment) or to active MAD therapy. Epidemiologic studies suggest that OSA is associated with insulin resistance independent of other known risk factors such as obesity. The cyclic intermittent hypoxia in OSA is the primary stimulus that leads to insulin resistance, a primary risk factor for the development of type 2 diabetes. There is an association between the level of hypoxic stress in OSA and insulin resistance. The overall hypothesis to be tested is that treatment of OSA with MAD will improve insulin sensitivity, increase levels of HMW (High-molecular- weight) adiponectin, and improve psychological adjustment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Apnea Syndromes
Keywords
Sleep Apnea Syndromes, Insulin Resistance, Mandibular advancement device

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Mandibular advancement device
Arm Type
Experimental
Arm Description
Subject is evaluated when receiving intervention with mandibular advancement device.
Arm Title
No mandibular advancement device
Arm Type
No Intervention
Arm Description
Subject is evaluated when not receiving treatment with mandibular advancement device.
Intervention Type
Device
Intervention Name(s)
Mandibular advancement device
Intervention Description
Mandibular advancement device made to subject specific specifications
Primary Outcome Measure Information:
Title
Treatment of OSA with mandibular advancement device results in improvements in insulin sensitivity
Time Frame
16 weeks
Secondary Outcome Measure Information:
Title
Treatment of OSA with mandibular advancement device increases the levels of high-molecular-weight adiponectin in the circulation
Time Frame
16 weeks
Title
Treatment of OSA with mandibular advancement device improves psychological adjustment.
Time Frame
16 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Apnea-hypopnea index (AHI) of at least 20 events/hr based on overnight polysomnography > 18 years of age Unable to tolerate or refuse CPAP treatment Exclusion Criteria: Known diabetes mellitus Body mass index (BMI) > 45 kg/m2 Uncontrolled hypertension Known congestive heart failure Use of illicit drugs Excessive alcohol consumption, defined as: More than 3 glasses of wine a day More than 3 beers a day More than 60 mL of hard liquor a day Room air oxyhemoglobin saturation < 90% Use of home oxygen Use of corticosteroids Unable to give voluntary consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ulysses Magalang, M.D.
Organizational Affiliation
Ohio State University
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Ohio State University
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Dental Device for Treatment of Sleep Apnea

We'll reach out to this number within 24 hrs